AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24206010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy (cold pack applied over abdomen and back for 10 minutes every 30 minutes during first phase of labour; cold pack over perineum for 5 minutes every 15 minutes during second phase)
Number of subjects: 64
Study 24206010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 64
Study 24206010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold therapy)
Number of subjects: 64
Study 20337606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab alone (BEVA group)
Number of subjects: 41
Study 20337606 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab in combination with photodynamic therapy (COMB group)
Number of subjects: 41
Study 19066436 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival suture removal 4 weeks postoperatively
Number of subjects: 69
Study 19066436 — intervention group
Group type: COMPARATOR
Intervention: Control group (suture remained in place)
Number of subjects: 69
Study 17242095 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran 2 mg
Number of subjects: 152
Study 17242095 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran 12 mg
Number of subjects: 152
Study 17242095 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran 28 mg
Number of subjects: 152
Study 17242095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 16286586 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Moderate Release paclitaxel-eluting stent
Number of subjects: 448
Study 16286586 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated Express2 stent)
Number of subjects: 448
Study 11929196 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (1.5g DHA/day for 2 months)
Number of subjects: 40
Study 11929196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mixed plant oil capsules for 2 months)
Number of subjects: 40
Study 10403065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (5HT1B/1D receptor agonist)
Number of subjects: 164
Study 10403065 — intervention group
Group type: COMPARATOR
Intervention: Usual migraine therapy
Number of subjects: 164
Study 7726322 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (12 g/day)
Number of subjects: 28
Study 7726322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2383198 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha‐isopropylester (PGF2 alpha‐IE) 0.5 microgram, twice daily for 1 week
Number of subjects: 30
Study 2383198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7239398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromopride (Cascapride)
Number of subjects: 0
Study 31830926 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGIS intervention (22-week programme)
Number of subjects: 0
Study 28027950 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Low-Fat diet
Number of subjects: 600
Study 28027950 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Low-Carbohydrate diet
Number of subjects: 600
Study 27978858 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT-based stress management intervention with facilitated bulletin board
Number of subjects: 90
Study 27978858 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT-based stress management intervention without facilitated bulletin board
Number of subjects: 90
Study 27978858 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 90
Study 24509270 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter intervention
Number of subjects: 229
Study 24509270 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 229
Study 22992070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra Abdominal Balloon Occlusion (IABO)
Number of subjects: 33
Study 22992070 — intervention group
Group type: COMPARATOR
Intervention: Control (no IABO)
Number of subjects: 33
Study 19887475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (800 mg)
Number of subjects: 25
Study 19887475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17848652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 16390
Study 17848652 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 16390
Study 15044183 — intervention group
Group type: EXPERIMENTAL
Intervention: LoCO(2) (8 mmHg below resting values)
Number of subjects: 8
Study 15044183 — intervention group
Group type: EXPERIMENTAL
Intervention: HiCO(2) (8 mmHg above resting values)
Number of subjects: 8
Study 11433046 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach intervention for families and physicians, including 2 meetings with a physician peer leader and feedback on previous prescribing rates. Parents received a CDC brochure on antibiotic use.
Number of subjects: 14468
Study 11433046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 14468
Study 11433046 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach intervention for families and physicians.
Number of subjects: 14468
Study 9614724 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Avonex)
Number of subjects: 0
Study 9614724 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1b (Betaferon)
Number of subjects: 0
Study 7996376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1600 mg/day)
Number of subjects: 16
Study 7996376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7996376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 16
Study 3054429 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol-insulin treatment
Number of subjects: 8
Study 3054429 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin treatment
Number of subjects: 8
Study 4873660 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 0
Study 4873660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0
Study 4873660 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 31129983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for nightmares delivered over 4 weeks in addition to treatment as usual (TAU)
Number of subjects: 24
Study 31129983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for nightmares
Number of subjects: 24
Study 31129983 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study 29061270 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 351
Study 29061270 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 351
Study 25933201 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of rhFGF-2/HA in the intrabony defect
Number of subjects: 30
Study 25933201 — intervention group
Group type: COMPARATOR
Intervention: Open debridement with papilla preservation flaps (Control)
Number of subjects: 30
Study 23959815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 267
Study 23959815 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine (ATX)
Number of subjects: 267
Study 21532516 — intervention group
Group type: COMPARATOR
Intervention: saline‐F
Number of subjects: 18
Study 21532516 — intervention group
Group type: COMPARATOR
Intervention: CMC‐F
Number of subjects: 18
Study 21532516 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐F
Number of subjects: 18
Study 18362510 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese adult PWS subjects
Number of subjects: 21
Study 16172169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing test in HOCM patients
Number of subjects: 22
Study 16172169 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 22
Study 16172169 — intervention group
Group type: COMPARATOR
Intervention: HNCM group
Number of subjects: 22
Study 16172169 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 22
Study 12906341 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of mental health clinical nurse specialist (CNS) care
Number of subjects: 268
Study 12906341 — intervention group
Group type: COMPARATOR
Intervention: Control firm physicians notified prior to encounter
Number of subjects: 268
Study 10789602 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release nifedipine
Number of subjects: 313
Study 10789602 — intervention group
Group type: EXPERIMENTAL
Intervention: temperature biofeedback
Number of subjects: 313
Study 10789602 — intervention group
Group type: COMPARATOR
Intervention: control (electromyographic) biofeedback
Number of subjects: 313
Study 9125101 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing
Number of subjects: 0
Study 9125101 — intervention group
Group type: COMPARATOR
Intervention: Distracting
Number of subjects: 0
Study 8450166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clentiazem 40 mg/day
Number of subjects: 199
Study 8450166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clentiazem 80 mg/day
Number of subjects: 199
Study 8450166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clentiazem 120 mg/day
Number of subjects: 199
Study 8450166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 3512795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizofenone
Number of subjects: 208
Study 3512795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 30337444 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR156597 Q2W
Number of subjects: 327
Study 30337444 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR156597 QW
Number of subjects: 327
Study 30337444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 28351412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol®
Number of subjects: 144
Study 28351412 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 144
Study 28351412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 25938830 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DCRT followed by TACE (Group A)
Number of subjects: 65
Study 25938830 — intervention group
Group type: COMPARATOR
Intervention: TACE followed by 3DCRT (Group B)
Number of subjects: 65
Study 23640005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Toner Device (PTD) with PFMT
Number of subjects: 40
Study 23640005 — intervention group
Group type: COMPARATOR
Intervention: Standard PFMT (ST)
Number of subjects: 40
Study 19804443 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) allergen inhalation challenge
Number of subjects: 6
Study 19804443 — intervention group
Group type: COMPARATOR
Intervention: Grass pollen (GP) allergen inhalation challenge
Number of subjects: 6
Study 18583910 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaSilk (with AEM 5772/5 antimicrobial finish)
Number of subjects: 30
Study 18583910 — intervention group
Group type: COMPARATOR
Intervention: Unmodified silk (without AEM 5772/5 antimicrobial finish)
Number of subjects: 30
Study 16902074 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized, quality recreation
Number of subjects: 0
Study 16902074 — intervention group
Group type: COMPARATOR
Intervention: Self‐financed recreation
Number of subjects: 0
Study 16902074 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized recreation
Number of subjects: 0
Study 12777279 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal
Number of subjects: 32
Study 12777279 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 32
Study 11044239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula presence
Number of subjects: 1824
Study 11044239 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors
Number of subjects: 1824
Study 11044239 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral vascular disease
Number of subjects: 1824
Study 11044239 — intervention group
Group type: EXPERIMENTAL
Intervention: Race (Black vs Non-Black)
Number of subjects: 1824
Study 11044239 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI)
Number of subjects: 1824
Study 11044239 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1824
Study 9323286 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose prednisolone (2 mg/kg per day as a single morning dose for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Number of subjects: 106
Study 9323286 — intervention group
Group type: COMPARATOR
Intervention: Divided-dose prednisolone (2 mg/kg per day in three divided doses for 2 weeks, followed by 1.5 mg/kg on alternate days for 4 weeks)
Number of subjects: 106
Study 9323286 — intervention group
Group type: COMPARATOR
Intervention: Both groups (single-dose and divided-dose)
Number of subjects: 106
Study 8203183 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (5MI), n=23
Number of subjects: 42
Study 8203183 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=19
Number of subjects: 42
Study 3910710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 126
Study 3910710 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 126
Study 31391092 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinang formulation (YNF) plus conventional therapy
Number of subjects: 72
Study 31391092 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus conventional therapy
Number of subjects: 72
Study 28777672 — intervention group
Group type: EXPERIMENTAL
Intervention: Grounded khat leaves extract (45 g)
Number of subjects: 30
Study 28777672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (juice only)
Number of subjects: 30
Study 26952221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mg intrathecal morphine (Group I, n=22)
Number of subjects: 48
Study 26952221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4mg intrathecal morphine (Group II, n=26)
Number of subjects: 48
Study 24254493 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 150 pps
Number of subjects: 20
Study 24254493 — intervention group
Group type: COMPARATOR
Intervention: TENS at 60 pps
Number of subjects: 20
Study 21931327 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioural treatment (FBBT)
Number of subjects: 72
Study 21931327 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 72
Study 21029897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral implantation of AcrySof IQ ReSTOR +3.0 IOL (model SN6AD1)
Number of subjects: 147
Study 18572432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg + Acetaminophen 1000 mg (RA)
Number of subjects: 173
Study 18572432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 173
Study 18572432 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen alone (A)
Number of subjects: 173
Study 18572432 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan alone (R)
Number of subjects: 173
Study 11750189 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9142805 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ; 5/25 mg/[kg x d])
Number of subjects: 19
Study 9142805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8433249 — intervention group
Group type: EXPERIMENTAL
Intervention: Decalcified freeze-dried bone allograft (DFDBA)
Number of subjects: 10
Study 8433249 — intervention group
Group type: COMPARATOR
Intervention: Flap procedure for debridement (FPD)
Number of subjects: 10
Study 8433249 — intervention group
Group type: COMPARATOR
Intervention: Polylactic acid (PLA) granules
Number of subjects: 10
Study 3315397 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% amino acid dialysis solution
Number of subjects: 0
Study 3315397 — intervention group
Group type: COMPARATOR
Intervention: 1.36% glucose
Number of subjects: 0
Study 30014516 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (20mg)
Number of subjects: 50
Study 30014516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28086943 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye intake (170 g/day) and vigorous physical activity (3 × 45 minutes/week) for 6 months
Number of subjects: 26
Study 28086943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 28086943 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye intake and vigorous physical activity
Number of subjects: 26
Study 24366918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly
Number of subjects: 141
Study 24160383 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical simulator training
Number of subjects: 21
Study 24160383 — intervention group
Group type: COMPARATOR
Intervention: Traditional wet-lab training
Number of subjects: 21
Study 21912474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg twice daily for 2 weeks, amoxicillin 1.0 g and clarithromycin 0.5 g twice daily for 1 week
Number of subjects: 195
Study 21912474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 21912474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole, amoxicillin, and clarithromycin
Number of subjects: 195
Study 19138183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B CrossAction (CA) used for 1 min
Number of subjects: 40
Study 19138183 — intervention group
Group type: COMPARATOR
Intervention: ADA manual toothbrush used for 2 min
Number of subjects: 40
Study 19138183 — intervention group
Group type: COMPARATOR
Intervention: ADA manual toothbrush used for 5 min
Number of subjects: 40
Study 16912957 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1 3435C‐‐>T variant
Number of subjects: 0
Study 12960415 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 10
Study 12960415 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 10
Study 12960415 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-switch from deferiprone to deferoxamine
Number of subjects: 10
Study 12960415 — intervention group
Group type: COMPARATOR
Intervention: Post-switch from deferoxamine to deferiprone
Number of subjects: 10
Study 10975769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 12 weeks
Number of subjects: 104
Study 10975769 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 104
Study 10975769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 12 weeks (only patients with normal mucosa at baseline)
Number of subjects: 104
Study 10975769 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks (only patients with normal mucosa at baseline)
Number of subjects: 104
Study 8931749 — intervention group
Group type: EXPERIMENTAL
Intervention: T-activin therapy
Number of subjects: 17
Study 8931749 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 17
Study 1306673 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Precision toothbrush
Number of subjects: 126
Study 1306673 — intervention group
Group type: COMPARATOR
Intervention: Oral-B 40 toothbrush
Number of subjects: 126
Study 1306673 — intervention group
Group type: COMPARATOR
Intervention: Reach Full-Head soft toothbrush
Number of subjects: 126
Study 31618138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast speech rate condition
Number of subjects: 50
Study 31618138 — intervention group
Group type: COMPARATOR
Intervention: Slow speech rate condition
Number of subjects: 50
Study 28248711 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27150028 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-1233 in acute PE (1st day)
Number of subjects: 72
Study 23725026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical freeze-dried bone allograft (FDBA)
Number of subjects: 40
Study 23725026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous freeze-dried bone allograft (FDBA)
Number of subjects: 40
Study 22353027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to prosmoking media
Number of subjects: 135
Study 22353027 — intervention group
Group type: COMPARATOR
Intervention: Control prompts
Number of subjects: 135
Study 22009784 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-sided augmentation (MSA)
Number of subjects: 42
Study 22009784 — intervention group
Group type: COMPARATOR
Intervention: Lateral-sided augmentation (LSA)
Number of subjects: 42
Study 18279486 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic visor respirator
Number of subjects: 22
Study 18279486 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular visor respirator
Number of subjects: 22
Study 18279486 — intervention group
Group type: COMPARATOR
Intervention: No mask (unprotected)
Number of subjects: 22
Study 16106120 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device therapy
Number of subjects: 0
Study 16106120 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile devices
Number of subjects: 0
Study 12899586 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg twice daily, for 4 weeks
Number of subjects: 14
Study 10229434 — intervention group
Group type: EXPERIMENTAL
Intervention: BASRI (Bath Ankylosing Spondylitis Radiology Index) scoring system
Number of subjects: 550
Study 10229434 — intervention group
Group type: EXPERIMENTAL
Intervention: BASRI scoring system
Number of subjects: 550
Study 8697339 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms misoprostol inserted vaginally
Number of subjects: 62
Study 8697339 — intervention group
Group type: COMPARATOR
Intervention: Placebo similarly applied
Number of subjects: 62
Study 2059974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrices containing 1,000 ppm F as sodium monofluorophosphate (SMFP)
Number of subjects: 0